What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 1, Pre-Registered Trial).

December 8, 2025Blood

Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia

View Full Paper

Ask AI

Bookmark

Authors

Phase II trial demonstrates CAR T-cell therapy improves survival rates in high-risk B-ALL, suggesting new treatment options.

HuCART19 therapy showed durable remissions in high-risk relapsed/refractory B-cell acute lymphoblastic leukemia.
After 2 years, event-free survival was 65%, highlighting the therapy's potential.
Phase I trial previously indicated promising responses in CAR-naïve and CAR-exposed cohorts.
Cytokine release syndrome occurred in 90% of CAR-naïve patients, emphasizing treatment monitoring.

Li et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Phase II trial demonstrates CAR T-cell therapy improves survival rates in high-risk B-ALL, suggesting new treatment options.

HuCART19 therapy showed durable remissions in high-risk relapsed/refractory B-cell acute lymphoblastic leukemia.
After 2 years, event-free survival was 65%, highlighting the therapy's potential.
Phase I trial previously indicated promising responses in CAR-naïve and CAR-exposed cohorts.
Cytokine release syndrome occurred in 90% of CAR-naïve patients, emphasizing treatment monitoring.

Li et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark